Institutions Shift Positions in Major Blue-Chip Stocks

KBC Group NV disclosed a series of notable fourth‑quarter changes across its U.S. equity holdings. The firm boosted its stake in ResMed Inc. (RMD) by 126.9% to 237,604 shares, valued at $57.23 million and representing about 0.16% of the company. It also expanded its position in Regeneron Pharmaceuticals (REGN) by 14.9% to 38,215 shares worth $29.50 million.

In financials, KBC Group NV increased its holding in Principal Financial Group by 1,144.6%, ending the quarter with 397,070 shares valued at $35.03 million, or about 0.18% of the company. The firm raised its Ameriprise Financial stake by 12.2% to 150,606 shares worth $73.85 million, approximately 0.16% of the stock.

At the same time, KBC reduced exposure to several names. Its position in Arthur J. Gallagher & Co. fell 8.3% to 143,679 shares valued at $37.18 million. In Arch Capital Group, the firm cut its stake by 24.8% to 317,007 shares, worth $30.41 million and equal to about 0.09% of the insurer. KBC also trimmed its AMETEK holding by 9.3%, ending with 255,987 shares valued at $52.56 million.

KBC modestly increased its Medtronic (MDT) position by 5.2%, bringing its holding to 430,508 shares valued at $41.35 million. Across these names, institutional ownership remains high, with several companies reporting more than three‑quarters of their stock held by institutional investors.

Beyond KBC, other investors were active in insurance and financial stocks. Cwm LLC lifted its Arch Capital Group position by 4.1% to 268,083 shares valued at $25.72 million, while multiple managers added to positions in Principal Financial Group and Markel Group. Baxter Bros Inc. increased its Markel stake by 44.3% to 2,537 shares worth $5.45 million.

Analysts maintained generally constructive views. Arch Capital Group carries a consensus “Hold” rating with an average target price of $109.40, while Principal Financial Group also holds a “Hold” consensus and a $93.44 average target. Markel Group’s consensus rating is “Hold” with a $2,100 target, and Jack Henry & Associates is rated “Moderate Buy” with a consensus target of $200.15.

Insider transactions were notable. At Arch Capital Group, several executives, including the CEO and other insiders, sold shares in the first quarter, with company filings indicating multiple transactions but maintaining insider ownership at 3.30%. At Arthur J. Gallagher & Co., vice presidents Scott R. Hudson and Christopher E. Mead sold shares in March, while at Principal Financial Group the CEO sold stock in January. Merck, Ameriprise and Markel also reported executive share sales during the quarter.

Healthcare and biotech stocks attracted fresh institutional capital. Argo Wealth Advisory LLC initiated a new Amgen (AMGN) position of 8,130 shares valued at $2.66 million, making the stock its 22nd largest holding. Greenwood Capital Associates opened a new Merck & Co. stake of 10,346 shares worth about $1.09 million. Cwm LLC and KBC Group NV both increased their Regeneron (REGN) holdings, and KBC added to its positions in ResMed (RMD) and Medtronic (MDT).

Operationally, several of these companies recently reported earnings. Amgen (AMGN) posted quarterly revenue of $9.87 billion, up 8.6% year on year, and non-GAAP earnings per share (EPS) of $5.29, ahead of consensus, with full‑year 2026 non-GAAP EPS guidance of $21.60 to $23.00. Merck reported quarterly revenue of $16.40 billion, up 5.0%, and EPS of $2.04, also above expectations, and issued 2026 EPS guidance of $5.00 to $5.15.

Regeneron delivered revenue of $3.88 billion, up 2.5%, and EPS of $11.44, beating consensus, while raising its quarterly dividend to $0.94 per share. ResMed (RMD) reported quarterly revenue of $1.42 billion, up 11.0%, and EPS of $2.81. Medtronic posted $9.02 billion in revenue, a 5.8% increase, and EPS of $1.36.

Analyst coverage remained broadly positive. Amgen holds a consensus “Hold” rating with a $356.24 average price target, while Merck is rated “Moderate Buy” with an average $128.47 target. Regeneron also carries a “Moderate Buy” consensus and an $811.96 average target, and Medtronic is rated “Moderate Buy” with a $109.25 consensus target price.

In consumer staples, AE Wealth Management LLC trimmed its Procter & Gamble (PG) stake by 1.6% to 654,938 shares valued at $93.86 million. Large asset managers such as Vanguard and State Street modestly increased positions during the third quarter, contributing to institutional ownership of 65.77%.

Procter & Gamble (PG) shares recently traded around $143.16, with a 12‑month range of $137.62 to $171.65. The company reported quarterly EPS of $1.88 on revenue of $22.21 billion, a 1.5% year‑over‑year increase. It raised its quarterly dividend to $1.0885 per share, marking the 70th consecutive year of dividend growth and implying an annualized yield of about 3.0%.

Analyst sentiment on Procter & Gamble is mixed but generally favorable. The stock has a consensus “Moderate Buy” rating and an average price target of $163.16. Individual firms have recently adjusted targets, with UBS and Raymond James lowering their estimates, while JPMorgan (JPM) reduced its target price to $162 and maintained an “overweight” rating.

In industrial and technology names, AMETEK reported 13.4% revenue growth to $2.0 billion and EPS of $2.01, raising its dividend to $0.34 per quarter. Jack Henry & Associates reported 7.9% revenue growth to $611.18 million and EPS of $1.72, and also lifted its quarterly dividend to $0.61 per share. Both carry “Moderate Buy” consensus ratings and updated multi‑year EPS guidance.